NewsBenzingaAllogene Therapeutics annonce des données préliminaires de sécurité, d’efficacité et de traduction issues de son essai de phase 1 RESOLUTION d’ALLO-329 au congrès de l’American College of Rheumatology Allogene Therapeutics annonce des données préliminaires de sécurité, d’efficacité et de traduction issues de son essai de phase 1 RESOLUTION d’ALLO-329 au congrès de l’American College of Rheumatology Benzinga 2026.11.09 13:05 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients